Business
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at the Hangzhou site. The accomplishment not only marks a significant breakthrough as Asia's first 5,000L drug substance scale-up line utiliz
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20%- As the company's largest operational single-use bioreactor to date, the system triples total site capacity to 23,000L, enabling flexible scale-up solutions","length":538,"tagName":"p"},{"type":"text","content":"HANGZHOU, China, April 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at the Hangzhou site. The accomplishment not only marks a significant breakthrough as Asia's first 5,000L drug substance scale-up line utilizing SUBs, but also demonstrates the company's industry-leading capabilities in single-use technology (SUT) application for large-scale production, reaffirming its position at the forefront of advanced manufacturing solutions.","length":796,"tagName":"p"},{"type":"text","content":"WuXi Biologics' innovative process technologies have been instrumental in achieving remarkable PPQ outcomes: Protein production costs per gram were reduced by nearly 70%, while advanced mass transfer technology delivered a 20% increase in protein yield per batch. In 2024, the company commissioned three 5,000L single-use bioreactors, its largest operational SUBs to date, and the systems achieved successful commercial-scales engineering run within the same year. Integrated with four existing 2,000L single-use technology production lines at the same facility, the site's total capacity is elevated from 8,000L to 23,000L.","length":643,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics, commented, "The successful completion of the first commercial PPQ campaign of the 15,000-liter single-use bioreactors demonstrates our continued leadership in commercial biomanuf...